Literature DB >> 8830012

The ability of beta-lactam antibiotics to select mutants with derepressed beta-lactamase synthesis from Citrobacter freundii.

P Stapleton1, K Shannon, I Phillips.   

Abstract

The ability of beta-lactam compounds to induce synthesis of the class C beta-lactamase of Citrobacter freundii was assessed both directly and indirectly, the latter by measurement of the different susceptibilities of strains with inducible and depressed beta-lactamase synthesis and those of a beta-lactamase-negative strain. Most beta-lactam compounds were poor inducers but ampicillin, amoxycillin and cephalexin were moderately good inducers and cefoxitin, imipenem and meropenem were strong inducers. The ability of the compounds to select mutants in which the synthesis of the beta-lactamase was derepressed was also assessed. Imipenem and temocillin, which had a high degree of stability to the beta-lactamase failed to select such mutants or were very poor selectors. In contrast, most other compounds showed considerable lability to the beta-lactamase and readily selected derepressed mutants, whether they were strong inducers of beta-lactamase synthesis (for example cefoxitin) or poor inducers (cefotaxime, ceftazidime and many other compounds). Thus it appears that lability to the beta-lactamase is a more important factor in determining whether or not a compound will select derepressed mutants than the power of the compound as an inducer of beta-lactamase synthesis, since induction results in the production of less beta-lactamase than derepression as a result of mutation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8830012     DOI: 10.1093/jac/36.3.483

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein.

Authors:  P D Stapleton; K P Shannon; G L French
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  DNA sequence differences of ampD mutants of Citrobacter freundii.

Authors:  P Stapleton; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

4.  Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.

Authors:  P D Stapleton; K P Shannon; G L French
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 5.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

Review 6.  Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic.

Authors:  Tommaso Lupia; Ilaria De Benedetto; Giacomo Stroffolini; Stefano Di Bella; Simone Mornese Pinna; Verena Zerbato; Barbara Rizzello; Roberta Bosio; Nour Shbaklo; Silvia Corcione; Francesco Giuseppe De Rosa
Journal:  Antibiotics (Basel)       Date:  2022-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.